Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Sanofi and Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, have announced a collaboration to co-develop and co-commercialize asset TEV'574, which is currently in Phase IIb clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
"Anti-TL1As are a promising class of therapies, and we believe TEV'574 has the potential to be the best-in-class option for people suffering from serious gastrointestinal diseases." This collaboration reinforces our commitment to deve...